Lung Cancer Diagnostic and Screening Global Market Report 2024

The lung cancer diagnostic and screening market size has grown rapidly in recent years. It will grow from $2.11 billion in 2023 to $2.32 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The expansion observed in the historical period can be credited to several factors, including the growth of digital imaging, the standardization of screening protocols, public health initiatives aimed at reducing tobacco use, the establishment of cancer registries, and advancements in pathology analysis.

The lung cancer diagnostic and screening market size is expected to see strong growth in the next few years. It will grow to $3.3 billion in 2028 at a compound annual growth rate (CAGR) of 9.2%. The anticipated growth in the forecast period is driven by several factors, including the increasing incidence of lung cancer, a growing emphasis on early detection, the expansion of high-risk screening programs, a shift towards personalized medicine, and government initiatives and funding. Key trends expected in the forecast period encompass the emergence of novel screening modalities, advancements in biomarker testing, the integration of artificial intelligence (AI), an increase in the adoption of liquid biopsy techniques, a focus on early stage detection, and the expansion of low-dose CT screening programs.

The projected increase in the prevalence of lung cancer is poised to drive the growth of the lung cancer diagnostic and screening market in the foreseeable future. Lung cancer, characterized by symptoms such as coughing, chest pain, and difficulty breathing, is a malignant disease marked by the uncontrolled proliferation of abnormal cells in lung tissues. Diagnostic and screening methods for lung cancer play a crucial role in early detection, utilizing various tests such as incisional biopsy and bronchoscopy. As of January 2023, data from the American Cancer Society indicates approximately 238,340 new cases of lung cancer in the United States, with 127,070 reported deaths. This surge in lung cancer cases underscores the significance of diagnostic and screening measures, thereby fueling the growth of the lung cancer diagnostic and screening market.

The upward trajectory of healthcare expenditures is anticipated to further propel the expansion of the lung cancer diagnostic and screening market. Healthcare expenditures encompass the total costs associated with providing and receiving medical services, treatments, and healthcare-related goods and activities. The implementation of lung cancer diagnostic and screening methods contributes to healthcare expenditures by facilitating early detection, potentially reducing long-term treatment costs, and enhancing patient outcomes. In November 2022, the Canadian Institute for Health Information (CIHI) projected a 0.8% increase in total health spending in Canada, reaching $331 billion in 2022 from $328 billion in 2021. This upward trend in healthcare expenditures is a key driver in the growth of the lung cancer diagnostic and screening market.

Technological innovations stand out as a prominent trend gaining traction in the lung cancer diagnostics and screening market. Leading companies within this sector are actively introducing cutting-edge technologies to maintain their competitive positions. A notable example is Auris Health, a US-based robotic medical company, which, in December 2021, unveiled the MONARCH Robotic-Assisted Bronchoscopy procedure. This groundbreaking procedure allows physicians to accurately diagnose small and hard-to-reach lung nodules, facilitating biopsies for the early diagnosis and treatment of lung diseases.

Major players in the lung cancer diagnostics and screening market are strategically focused on the development of blood-based tests that leverage machine learning, specifically whole-genome machine learning. This approach involves applying machine learning algorithms to analyze and interpret comprehensive sets of genetic information, encompassing an organism's entire genome. DELFI Diagnostics Inc., a US-based developer of accessible blood-based tests, exemplified this strategy in October 2023 with the launch of FirstLook Lung. This blood test utilizes whole-genome machine learning to analyze cell-free DNA fragments, enhancing lung cancer screening with an impressive 99.7% negative predictive value (NPV). Designed for routine blood work, the test identifies individuals with potential lung cancer, including those in early stages, aiming to improve population health by addressing low uptake of low-dose computed tomography (LDCT) screening.

In January 2022, RadNet Inc., a US-based radiology company, acquired Aidence BV for an undisclosed amount. This acquisition is anticipated to strengthen RadNet Inc.'s leadership in developing and deploying artificial intelligence (AI) for improved patient care and health. It also accelerates their growth and innovation pipeline, providing automated and integrated AI oncology solutions for clinicians. Aidence BV, based in the Netherlands, is a healthcare technology company with a focus on clinical solutions for lung cancer screening and pulmonary nodule treatment.

Major companies operating in the lung cancer diagnostic and screening market report are Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories Inc., Medtronic Plc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, Eon Health Inc., Oncimmune Holdings PLC, Broncus Medical Inc., OncoCyte, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix, iDNA.

North America was the largest region in the lung cancer diagnostic and screening market in 2023. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lung cancer diagnostic and screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary products associated with lung cancer diagnostics and screening include instruments, consumables, and accessories. Instruments are products utilized to analyze the results of diagnostic tests and process samples for diagnostic purposes. Various tests, such as biomarker tests, imaging tests, biopsy, and blood tests, are employed for different cancer types, including non-small cell lung cancer and small cell lung cancer. These diagnostic tools find application across diverse end-users, including hospitals, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.

The lung cancer diagnostics and screening market research report are one of a series of new reports that provides lung cancer diagnostics and screening market statistics, including lung cancer diagnostics and screening industry global market size, regional shares, competitors with a lung cancer diagnostics and screening market share, detailed lung cancer diagnostics and screening market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer diagnostics and screening industry. This lung cancer diagnostics and screening market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lung cancer diagnosis and screening market consists of revenues earned by entities by providing positron emission tomography (PET) scanners, and bronchoscopy. The market value includes the value of related goods sold by the service provider or included within the service offering. The lung cancer diagnosis and screening market also includes sales of products such as liquid biopsy kits, molecular testing kits, and biopsy tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.